ERBB2 and invasive lobular breast carcinoma: Previous reports suggested that ERBB2 mutations might be enriched in a specific histological subtype, invasive lobular carcinoma (ILC) [12, 20], which account for 5-15 % of invasive breast tumors [21, 22].